Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure

Kidney International

Volumn 79, Issue 2, 2011, Pages 169-178

  Linkermann, Andreas ^a   Himmerkus, Nina ^a   Rölver, Lars ^a   Keyser, Kirsten A ^a   Steen, Philip ^a   Bräsen, Jan Hinrich ^a   Bleich, Markus ^a   Kunzendorf, Ulrich ^a   Krautwald, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

acute kidney injury; apoptosis; cisplatin induced nephropathy; Fas ligand

Indexed keywords

CISPLATIN; CREATININE; FAS LIGAND; GREEN FLUORESCENT PROTEIN; MFL3 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CISPLATIN INDUCED NEPHROPATHY; CONTROLLED STUDY; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY TUBULE; MALE; MORPHOLOGY; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE; THICK ASCENDING LIMB; TRANSGENE; UREA BLOOD LEVEL;

EID: 78650875224     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.317     Document Type: Article

References (30)

1. Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298.
2. Sanz AB, Santamaria B, Ruiz-Ortega M et al. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008; 19: 1634-1642.
3. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-542.
4. Lettau M, Schmidt H, Kabelitz D et al. Secretory lysosomes and their cargo in T and NK cells. Immunol Lett 2007; 108: 10-19.
5. Linkermann A, Qian J, Janssen O. Slowly getting a clue on CD95 ligand biology. Biochem Pharmacol 2003; 66: 1417-1426.
6. Kirkin V, Cahuzac N, Guardiola-Serrano F et al. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ 2007; 14: 1678-1687.
7. Schulte M, Reiss K, Lettau M et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activationinduced cell death. Cell Death Differ 2007; 14: 1040-1049.
8. Linkermann A, Qian J, Lettau M et al. Considering Fas ligand as a target for therapy. Expert Opin Ther Targets 2005; 9: 119-134.
9. Lorz C, Ortiz A, Justo P et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000; 11: 1266-1277.
10. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. Nephrol Dial Transplant 1999; 14: 1831-1834.
11. Schrier RW. Cancer therapy and renal injury. J Clin Invest 2002; 110: 743-745.
12. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8: 368-379.
13. Charlier C, Kintz P, Dubois N et al. Fatal overdosage with cisplatin. J Anal Toxicol 2004; 28: 138-140.
14. Lagrange JL, Cassuto-Viguier E, Barbe V et al. Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them. Eur J Cancer 1994; 30A: 2057-2060.
15. Tsuruya K, Ninomiya T, Tokumoto M et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63: 72-82. (Pubitemid 35463908)
16. Hamar P, Song E, Kokeny G et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 14883-14888.
17. Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
18. Liu M, Chien CC, Burne-Taney M et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 2006; 17: 765-774.
19. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
20. Demjen D, Klussmann S, Kleber S et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 2004; 10: 389-395.
21. Deng J, Kohda Y, Chiao H et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60: 2118-2128.
22. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842.
23. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289: F166-F174.
24. Tsuruya K, Tokumoto M, Ninomiya T et al. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 2003; 285: F208-F218. (Pubitemid 36871193)
25. Karray S, Kress C, Cuvellier S et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004; 172: 2118-2125.
26. Martin-Villalba A, Herr I, Jeremias I et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis- inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 1999; 19: 3809-3817.
27. Krautwald S, Ziegler E, Roelver L et al. Effective blockage of both the extrinsic and intrinsic pathway of apoptosis in mice by TAT-crmA. J Biol Chem 2010; 285: 19997-20005.
28. Brasen JH, Nieminen-Kelha M, Markmann D et al. Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. Kidney Int 2005; 67: 1583-1594.
29. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998; 101: 777-782.
30. Schafer JA, Watkins ML, Li L et al. A simplified method for isolation of large numbers of defined nephron segments. Am J Physiol 1997; 273: F650-F657.